SCHEMBL682485

SCHEMBL682485

CCOc1ccc(Br)cc1OC1CCCC1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.57
NPY1R P25929 1/20 0.56
NPY2R P49146 1/20 0.56
PDE4B Q07343 3/20 0.48
PDE3A Q14432 1/20 0.48
SLC6A4 P31645 7/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
HTR6 P50406 2/20 0.46
HTR2C P28335 1/20 0.45
HTR2B P41595 1/20 0.45
PDE4A P27815 2/20 0.44
PDE4C Q08493 2/20 0.44
PDE4D Q08499 2/20 0.44
PDE7A Q13946 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL705028 0.97 POLB (0.57) POLBNPY1RNPY2RPDE4BPDE3A
SCHEMBL129356 0.82 PDE4A (0.59) POLBNPY1RNPY2RPDE4BPDE4A
SCHEMBL128455 0.82 NPY1R (0.50) POLBNPY1RNPY2RSLC6A4HTR6
SCHEMBL5704271 0.81 PDE4A (0.57) POLBNPY1RNPY2RPDE4BPDE4A
SCHEMBL182753 0.79 TSHR (0.56) POLBPDE3AHPGDTSHRPDE4A
SCHEMBL31096231 0.79 TSHR (0.56) POLBPDE3AHPGDTSHRPDE4A
SCHEMBL7376963 0.79 HTT (0.52) POLBPDE4BPDE3APDE4APDE4C
SCHEMBL130569 0.79 PDE4A (0.55) POLBNPY1RNPY2RPDE4BPDE4A
SCHEMBL133005 0.78 PDE4A (0.50) POLBNPY1RNPY2RPDE4BSLC6A4
SCHEMBL31096114 0.78 PDE4A (0.50) POLBNPY1RNPY2RPDE4BSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624200-B2 Therapeutic piperazines DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2017-04-18 US disclosed
US-9624200-B2 Therapeutic piperazines DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2017-04-18 US disclosed
US-9624200-B2 Therapeutic piperazines DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2017-04-18 US disclosed
US-20150087645-A1 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. 2015-03-26 US disclosed
US-20150087645-A1 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. 2015-03-26 US disclosed
US-20150087645-A1 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. 2015-03-26 US disclosed
US-8927546-B2 Therapeutic piperazines DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2015-01-06 US disclosed
US-8927546-B2 Therapeutic piperazines DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2015-01-06 US disclosed
US-8927546-B2 Therapeutic piperazines DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2015-01-06 US disclosed
EP-2643000-A2 THERAPEUTIC PIPERAZINES Dart Neuroscience (Cayman) Ltd (KY) 2013-10-02 EP disclosed
WO-2012040258-A2 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. (US) 2012-03-29 WO disclosed
WO-2012040258-A2 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. (US) 2012-03-29 WO disclosed
US-20110065691-A1 THERAPEUTIC PIPERAZINES DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2011-03-17 US disclosed
US-20110065691-A1 THERAPEUTIC PIPERAZINES DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2011-03-17 US disclosed
US-20110065691-A1 THERAPEUTIC PIPERAZINES DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087645-A1 THERAPEUTIC PIPERAZINES PDE4A, PDE4B, PDE4D POLB 3240/4885NPY1R 229/4885NPY2R 226/4885
US-20110065691-A1 THERAPEUTIC PIPERAZINES PDE4A, PDE4B, PDE4D POLB 3240/4885NPY1R 229/4885NPY2R 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.